Amgen Inc. (NASDAQ:AMGN) Shares Bought by FMB Wealth Management

FMB Wealth Management grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,147 shares of the medical research company’s stock after purchasing an additional 71 shares during the quarter. Amgen makes up 1.2% of FMB Wealth Management’s portfolio, making the stock its 21st largest holding. FMB Wealth Management’s holdings in Amgen were worth $2,227,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. Centricity Wealth Management LLC acquired a new position in shares of Amgen during the 4th quarter valued at $25,000. Pinney & Scofield Inc. acquired a new position in Amgen during the fourth quarter worth about $26,000. Ritter Daniher Financial Advisory LLC DE lifted its holdings in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 51 shares during the last quarter. Synergy Investment Management LLC bought a new position in shares of Amgen during the 4th quarter valued at about $34,000. Finally, Atala Financial Inc bought a new stake in shares of Amgen in the 4th quarter worth approximately $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of AMGN stock opened at $291.81 on Thursday. The stock has a 50 day moving average of $280.88 and a two-hundred day moving average of $285.46. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The company has a market capitalization of $156.91 billion, a P/E ratio of 38.65, a P/E/G ratio of 2.63 and a beta of 0.51. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same period in the prior year, the company posted $3.96 earnings per share. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. As a group, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on AMGN. Cantor Fitzgerald began coverage on shares of Amgen in a report on Tuesday, April 22nd. They set a “neutral” rating and a $305.00 target price for the company. Guggenheim began coverage on Amgen in a research note on Tuesday, May 20th. They set a “neutral” rating and a $288.00 price objective for the company. Erste Group Bank lowered Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Mizuho increased their price target on Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research report on Wednesday, May 7th. Finally, UBS Group reissued a “neutral” rating and issued a $315.00 price target (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $309.22.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the business’s stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president now owns 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.76% of the stock is owned by company insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.